arXiv 2509.04939

The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors

By Linh Nguyen Phuong, Frederic Fina, et al.

Published 2025-09-05

Wiki summary

Explore the paper's summary, context, and related research on Papiers.

Background: Many advanced cancer patients experience progression under immune-checkpoint inhibitors (ICIs). Circulating cell-free DNA (cfDNA) size profiles offer a promising noninvasive multi-cancer approach to monitor and predict immunotherapy response. Methods: In the SChISM (Size CfDNA Immunotherapy Signature Monitoring) study (NCT05083494), pre-treatment plasmatic cfDNA size profiles from 126 ICI-treated advance…

View the original paper on arXiv